GrowingWithAK

Mirae Asset Nifty 500 Healthcare ETF

Exchange Traded Funds (ETFs) · Equity ETF · Regular · IDCW

Regular TER: 0.35% · as of

2026-02-11 → 2026-10-22

min ₹17.63 change +9.3% max ₹22.09

₹20.1539

as of 2026-10-22 · +0.03% vs 2026-10-21

2026-02-11

AMFI archive begins Apr 2006

-8.81%

trough 2026-10-21 (since archive start)

insufficient data

How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.

Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year
2026 · · -5.2 +6.3 +4.8 +5.2 +3.4 +1.5 -3.8 -4.7 · · +6.9
Avg · · -5.2 +6.3 +4.8 +5.2 +3.4 +1.5 -3.8 · · · ·

All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row.

Equity 100.0%
Equity split: Large 36.0% Mid 45.6% Small 18.3%

Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).

  • Large Cap 36.0%
  • Mid Cap 45.7%
  • Small Cap 18.3%
· vs · share of this fund's AUM that sits in stocks the index also includes

32.7%

5 of 44 holdings are index members

Mostly stocks outside the benchmark universe

As of 2026-09-30

How to read this: This number shows whether the fund invests in the same stocks as the index. It does not show whether the fund weights those stocks like the index. A low number (say below 60%) means the fund holds a meaningful share in stocks the index doesn't carry at all (typical of sectoral, small-cap-tilted or international funds vs a broad benchmark). A high number (80%+) is normal for any large-cap or flexi-cap fund, because Indian active funds mostly pick from the same large and mid-cap stocks as the Nifty 500. It does not on its own signal a closet index fund; to identify that you'd need per-stock weight comparison, which requires index constituent weights we don't currently ingest.

Stock Sector % of fund
Sun Pharmaceutical Industries Ltd. Pharmaceuticals & Biotechnology 10.13%
Divi's Laboratories Ltd. Pharmaceuticals & Biotechnology 8.76%
Apollo Hospitals Enterprise Ltd. Healthcare Services 6.24%
Laurus Labs Ltd. Pharmaceuticals & Biotechnology 5.72%
Cipla Ltd. Pharmaceuticals & Biotechnology 5.62%
Dr. Reddy's Laboratories Ltd. Pharmaceuticals & Biotechnology 5.58%
Torrent Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology 5.24%
Max Healthcare Institute Ltd. Healthcare Services 5.13%
Lupin Ltd. Pharmaceuticals & Biotechnology 3.66%
Aurobindo Pharma Ltd. Pharmaceuticals & Biotechnology 3.43%
Fortis Healthcare Ltd. Healthcare Services 2.98%
Glenmark Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology 2.61%
Alkem Laboratories Ltd. Pharmaceuticals & Biotechnology 2.31%
Zydus Lifesciences Ltd. Pharmaceuticals & Biotechnology 2.13%
Mankind Pharma Ltd. Pharmaceuticals & Biotechnology 2.10%
IPCA Laboratories Ltd. Pharmaceuticals & Biotechnology 1.99%
Biocon Ltd. Pharmaceuticals & Biotechnology 1.91%
Gland Pharma Ltd. Pharmaceuticals & Biotechnology 1.71%
Sai Life Sciences Ltd. Pharmaceuticals & Biotechnology 1.56%
Krishna Institute of Medical Sciences Ltd. Healthcare Services 1.48%
Healthcare: 100.0%
  • Healthcare 100.0%

Sharpe

+2.02

excess return per unit of total volatility

Sortino

+3.02

excess return per unit of downside vol

Calmar

—

CAGR / |max DD| in window

Beta vs benchmark

+0.51

scheme sensitivity to benchmark moves

Tracking error

+14.61%

annualised stdev of (scheme − benchmark)

Up capture

+65.9%

% of benchmark gain captured on up days

Down capture

+26.3%

% of benchmark loss participated in

Risk-free rate assumed 6.0% annualised. Benchmark = Nifty 50 TRI (assigned by category mapping).

Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.